In March 2018, I have led licensing and equity investment agreements with Harvard, and since then have been responsible for global business development projects.

“I am responsible for business development at Voronoi. Voronoi is a company that has its strength in
making drug candidates with high target selectivity and low toxicity. To fully utilize our strengths, and
in order to proceed rapidly to the clinical stage, it is essential to have the right resource at the right
time. To make this happen, I am responsible for seeking collaboration with external partners and
business development opportunity.
There are a growing number of studies to determine the safety of drug candidates, and a variety of
disease-specific animal studies. We collaborate with qualified CROs for early stage studies, and
depending on the indications, conducting joint research with leading research institutes.
In March 2018, Voronoi signed a licensing agreement with Harvard Dana-Faber Cancer Institute.
While Dana-Faber Cancer Institute has tough internal criteria in selecting partners for licensing
agreement, I took the responsibility of the whole deal process including strategy, legal advice, patent
transfer, and others.
In addition, to accelerate progress of Voronoi’s lung cancer pipeline, I worked for recruiting Dr. Pasi
Janne, who is an authority of EGFR lung cancer field, as our Science Advisory Board. Now I spend
most of my time communicating with leading pharmaceutical companies to conduct collaboration.
Prior to joining Voronoi, I worked for a hedge fund in San Francisco, mainly macro investment, and
have managed to fund a $400 million from CALPERS(California Civil Service Pension).”